Chemotherapy combined with immunotherapy vs. chemotherapy: comparison of safety and efficacy in adjuvant therapy for intrahepatic cholangiocarcinoma - Takeaways - MDSpire

Chemotherapy combined with immunotherapy vs. chemotherapy: comparison of safety and efficacy in adjuvant therapy for intrahepatic cholangiocarcinoma

  • By

  • Lu Yang

  • Haijing Zheng

  • Zhaolong Pan

  • Dongyang Li

  • Yunlong Cui

  • Huikai Li

  • Qiang Wu

  • Tianqiang Song

  • Qiang Li

  • Wei Zhang

  • June 22, 2026

  • 0 min

Share

  • 1

    This study analyzed data from 232 patients with intrahepatic cholangiocarcinoma treated at Tianjin Medical University Cancer Institute from 2011 to 2023.

  • 2

    Patients were divided into five groups, including those receiving gemcitabine plus oxaliplatin and capecitabine, to compare efficacy and safety.

  • 3

    Significant differences in recurrence-free survival and overall survival were observed between the chemotherapy group and the non-adjuvant treatment group.

  • 4

    The gemcitabine plus oxaliplatin group had a higher incidence of grade 3-4 adverse reactions compared to capecitabine.

  • 5

    Immunotherapy did not show overall benefit but may improve outcomes in patients with elevated CA19-9 or ALP levels.

Original Source(s)

Chemotherapy combined with immunotherapy vs. chemotherapy: comparison of safety and efficacy in adjuvant therapy for intrahepatic cholangiocarcinoma

  • by Lu Yang, Haijing Zheng, Zhaolong Pan, Dongyang Li, Yunlong Cui, Huikai Li, Qiang Wu, Tianqiang Song, Qiang Li, Wei Zhang

  • June 22, 2026

Related Content

Editorial: Harnessing machine learning for enhanced biomedical diagnosis and early disease detection: bridging data science and healthcare

Oxidative stress and antioxidants in breast cancer: a double-edged sword

Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma